832

Learn how German hospitals use NUB 2026 to win InEK Status 1, negotiate innovation payments, and close DRG funding gaps with a practical step-by-step checklist.

NUB 2026 Germany: 11 Steps to Win InEK Status 1

Understand how German hospitals really use the NUB application process to secure InEK Status 1, negotiate innovation payments with sickness funds, and close DRG funding gaps for new medical technologies.

If you work in market access, reimbursement, coding, or hospital finance in Germany, the NUB procedure (Neue Untersuchungs- und Behandlungsmethoden) is no longer a minor administrative form. It is the central gateway for temporary reimbursement of new examination and treatment methods that are not yet adequately paid within the aG-DRG system. The NUB inquiry closes the gap between early clinical use and full DRG or ZE inclusion.

On 30 January 2025, the Institute for the Hospital Remuneration System (InEK) released the latest NUB decisions for applications submitted in 2024:

• 1,025 hospital NUB applications submitted
• 300 technologies (≈29%) granted Status 1
• 13 technologies granted differentiated Status 1
• Most Status 1 approvals again concentrated in cardiovascular, endovascular, neuromodulation, extracorporeal support, gastrointestinal and complex reconstructive surgery – exactly the areas where DRGs are known to under-represent real device and procedure costs.

For these 300 technologies, NUB Status 1 unlocks the ability to negotiate case-based innovation payments (NUB-Entgelte) with sickness funds – often worth thousands of euros per case. In a hospital financing environment where G-DRGs systematically lag behind innovation, NUB has become a financial survival tool for high-cost, device-heavy procedures.

If you are planning a NUB 2026 strategy for your device or procedure, you need to understand how hospitals actually work with this instrument – not just what the law says. This guide explains:

• How the NUB mechanism functions inside German hospitals – from Medizincontrolling to Controlling & Finanzen and clinical leadership.
• Who really prepares the NUB application and why internal workflows and coding decisions determine InEK Status 1 vs Status 2.
• Why OPS coding and DRG mapping are the make-or-break factors for proving DRG underfunding.
• Which technology types NUB rewards (structural heart, neuromodulation, complex endovascular, regenerative surgery) – and which categories are systematically disadvantaged.
• How NUB innovation funding interacts with §137h / §137e SGB V benefit assessment and long-term DRG/ZE integration.

In 2026, NUB is not just a small “top-up” on the DRG. Used correctly, it is a strategic market access instrument, a data-generation bridge, and a cost-gap correction tool – but only for companies and hospitals that understand the coding and economic rules well enough to use it.

1. NUB 2026 Germany: Proven Strategies to Achieve InEK Status 1 and Fix DRG Underfunding

The German NUB process (Neue Untersuchungs- und Behandlungsmethoden) has become one of the most influential instruments for introducing new examination and treatment methods into the inpatient sector. Formally anchored in §6(2) KHEntgG, the NUB mechanism allows hospitals to obtain temporary innovation payments when DRG reimbursement does not yet reflect the true cost of an emerging technology.

In practical market access terms, NUB has evolved far beyond an administrative request. It is now a strategic reimbursement bridge: a way for hospitals to document DRG underfunding, justify early adoption, and negotiate supplementary payments with sickness funds until the aG-DRG system is updated.

On 30 January 2025, the Institute for the Hospital Remuneration System (InEK) released the latest NUB decisions for the 2024 application cycle. The outcomes again reveal clear patterns in how innovation is funded in Germany:

• 1,025 hospital applications submitted
• 300 technologies awarded Status 1 (≈29%)
• 13 technologies awarded differentiated Status 1-d
• Highest success in cardiovascular, endovascular, extracorporeal support, neuromodulation, GI, and complex reconstructive surgery—clinical areas where DRGs have long demonstrated structural underfunding.

For the 300 Status 1 technologies, InEK’s decision opens the door to case-based innovation payments (NUB-Entgelte). These are locally negotiated with each relevant sickness fund and often amount to several thousand euros per case, allowing hospitals to use novel devices without absorbing unsustainable cost deficits.

This is precisely why NUB has become a financial survival mechanism within a DRG environment that adjusts slowly to procedural and device innovation. In many specialties—structural heart, complex endovascular, implantable neuromodulation—hospital adoption would be impossible without NUB payments.

With the next application round approaching, NUB 2026 strategy requires a clear understanding of how the process works inside hospitals and how InEK evaluates “newness” and “inadequate reimbursement.” This includes:

• Correct OPS coding logic across all participating hospitals
• Transparent DRG mapping and demonstration of cost-weight mismatch
• Micro-costing evidence showing negative contribution margins
• Clinical justification anchored in medical necessity, not marketing claims
• Multi-centre consistency—InEK strongly favours convergent coding and costing practice

In short, NUB 2026 is not just a request for temporary additional reimbursement. It is a structured demonstration that:

1. The method is new in procedural or resource terms.
2. Existing DRGs do not adequately remunerate its use.
3. Hospitals would incur financial loss without a temporary supplement.
4. The method is clinically meaningful and justified.

Understanding these requirements allows manufacturers and hospitals to build a convincing NUB strategy that secures Status 1 rather than falling into Status 2 (“already adequately reimbursed”), which effectively blocks innovation payments for the entire year.

2. NUB 2026 Evaluation: Proven Steps to Achieve InEK Status 1 and Innovation Payment

The NUB 2026 evaluation pathway is a structured reimbursement mechanism that determines whether a new medical technology in Germany receives InEK Status 1 and becomes eligible for temporary innovation payments. This process is not administrative; it is an evidence-driven framework that integrates clinical novelty, OPS coding plausibility, DRG system transparency, and hospital cost-pathway analysis.

NUB sits at the intersection of §6(2) KHEntgG, the aG-DRG system, and emerging HTA pathways such as §137e and §137h SGB V. For 2026, InEK places heightened emphasis on coding consistency across centres, resource-use credibility, and evidence of structural underfunding. Technologies that cannot demonstrate these elements rarely achieve Status 1.

Stage 1: Providing Eligibility Through Novelty, Inpatient Value, and OPS Procedural Identity

Every NUB application begins with the question: Is this method new, inpatient-relevant, and assignable to a valid OPS code? Eligible technologies typically share four characteristics:

• High per-case cost (implant, system platform, advanced consumables)
• Inpatient clinical workflow (OR, cath lab, interventional suite)
• Clear procedural identity that maps to one or more OPS codes
• No DRG cost-weight representation due to lack of historical case data

InEK views NUB as a DRG-visible innovation pathway. Technologies without a verifiable procedural act—such as purely digital tools or outpatient diagnostics—almost never meet the eligibility threshold.

Stage 2 Coding and DRG Convergence: Demonstrating Cost-Weight Mismatch

This is the scientific core of the NUB mechanism. Each real-world case is grouped into a G-DRG using ICD-10-GM diagnoses and OPS procedural codes. NUB exists because certain innovative technologies:

• fall into legacy DRGs built around older, cheaper techniques,
• incur resource costs far higher than the assigned cost weight,
• generate negative contribution margins under routine reimbursement.

InEK awards Status 1 when hospitals present credible, multi-centre evidence that the DRG system underestimates the real cost of the new method.

Demonstrating “DRG underfunding” is now one of the most important determinants of Status 1 outcomes and aligns with the broader logic used in DRG refinements, ZE adjustments, and InEK’s annual costing cycles.

Stage 3 Building a Hospital Submission With Clear Coding Logic, Transparent Costs and Strong Clinical Justification

Although each application appears as a simple InEK form, the underlying work requires coordinated input from Medizincontrolling, Controlling & Finanzen and the clinical department. A scientifically robust submission includes:

• OPS coding rationale and cross-hospital coding synchronisation
• DRG mapping showing where the method groups and why the cost-weight is inadequate
• Micro-costing data (implant cost, OR/cath lab minutes, staffing, consumables, LOS, complication cost)
• Clinical justification—why the method is medically innovative and relevant
• Projected annual case volume to support realistic negotiations with sickness funds

While InEK does not request formal cost-effectiveness models, it expects a coherent cost-pathway narrative consistent with the logic of the German DRG system.

Stage 4 InEK Status Decision: Translating Evidence into Reimbursement

Once reviewed, InEK assigns one of four statuses:

• Status 1 — eligible for temporary innovation payments
• Status 1-d — eligible under defined indications, settings, or variants
• Status 2 — considered adequately reimbursed under current DRGs; no funding
• Status 3/4 — insufficient, inconsistent, or non-assessable data

A Status 1 decision allows each hospital to negotiate NUB-Entgelte (innovation payments) directly with sickness funds, typically amounting to several thousand euros per case depending on implant cost, complexity, and case mix.

Crucially, NUB also functions as a data-generation engine. Activity reimbursed under NUB produces high-resolution cost data that influence future G-DRG cost-weights, ZE creation, OPS refinements and even subsequent HTA assessments. This is why manufacturers increasingly integrate NUB strategy with §137e “coverage with evidence development” and long-term DRG/ZE integration planning.

In 2026, NUB is best understood as an evidence-translation pathway: clinical novelty → coding plausibility → DRG mismatch → InEK Status 1 → temporary innovation funding → long-term reimbursement integration.

3. Why Certain Technologies Consistently Achieve NUB Status 1: Scientific and Economic Rationale Behind InEK’s Decisions

Despite the apparent simplicity of the NUB application process, InEK’s assessments follow a recognisable pattern grounded in clinical novelty, procedural codability, and structural DRG underfunding. Certain technology classes repeatedly achieve Status 1, while others struggle to pass even basic eligibility thresholds. Understanding this pattern is essential for constructing a credible NUB 2026 strategy and for anticipating the evidence expected by InEK.

3.1 Structural Heart, Endovascular and Neuromodulation Devices: High-Certainty Winners in NUB

Across the last decade, the highest NUB success rates have consistently appeared in structural heart, complex endovascular, and implantable neuromodulation procedures. These technologies fulfil all three of the core scientific drivers of NUB eligibility:

• Clear procedural identity with well-defined OPS codes (e.g., valve implantation, neurostimulation leads, endovascular reconstruction)
• Substantial incremental resource use measurable in consumables, device cost, OR/cath lab minutes, perfusion support, or anaesthetic intensity
• Convergent coding behaviour across hospitals, producing strong cross-centre plausibility

The DRGs into which these procedures cluster—particularly in cardiology, vascular surgery and neurosurgery—were built around significantly lower-cost historical comparators. For example, legacy DRGs for PCI or simple vascular reconstructions do not contain the cost-weight capacity to absorb modern transcatheter implants, coated stents, or neuromodulation systems. This creates a predictable cost-weight mismatch, which is exactly what InEK prioritises.

3.2 Regenerative, Reconstructive and Biologic Techniques: Increasing Visibility Through DRG Misalignment

A second cluster of technologies gaining traction through NUB includes biologic implants, allografts, cartilage regeneration solutions, complex reconstructive techniques, and advanced wound therapies. Their success follows a similar rationale:

• Biologic materials have high per-case costs invisible to the DRG baseline
• Procedural resource intensity (OR minutes, multiple surgical teams, graft preparation) exceeds the cost-weight
• DRGs in reconstructive surgery evolve slowly, making innovation outpace reimbursement

Because these technologies alter tissue integration, biological stability, or healing trajectories, they often require new OPS codes or subcodes, and their cost profiles diverge significantly from traditional comparators. This structural misalignment is highly favoured by InEK’s evaluation logic.

3.3 Technologies That Rarely Succeed: The “NUB-Invisible” Categories

Some innovations struggle systematically under the NUB framework—not because they lack clinical value, but because they lack DRG-visible resource intensity or procedural mappability. These include:

• Purely digital solutions without a procedural act (AI algorithms, SaaS platforms)
• Low-cost disposables lacking significant incremental expenditure
• Outpatient-first technologies that do not change inpatient workflows
• Diagnostic tools without OPS-anchored intervention (unless linked to a high-cost procedure)

These categories fail primarily because NUB is fundamentally a procedure-based reimbursement mechanism. If the innovation does not alter the procedural, economic, or coding profile of a DRG case, InEK concludes that the technology is “adequately reimbursed”, resulting in Status 2.

3.4 The Scientific Logic Behind Failure: Why Status 2 is the Default Outcome

Status 2 is not a rejection—rather, it is the default conclusion when hospitals fail to present compelling evidence that the DRG system is structurally misaligned with the real cost of the method. The most common scientific reasons include:

• Insufficient evidence of cost-weight mismatch—no negative contribution margins demonstrated
• Inconsistent OPS coding across participating hospitals
• Low incremental resource use compared with the reference technique
• Insufficient volume projections to justify meaningful negotiation
• No clear procedural novelty (e.g., minor variation on an existing technique)

From a methodological viewpoint, InEK looks for coherence in how hospitals articulate clinical novelty, resource intensity, coding logic, and economic deficit. When any of these are underdeveloped, Status 2 becomes almost inevitable.

3.5 Predicting NUB 2026 Success: A Pathway-Based Model

Combining historical trends, coding science, DRG evolution and 2025 decisions, a predictable pattern emerges. The strongest candidates for NUB Status 1 in 2026 will be technologies that satisfy all three pillars:

• Pillar 1 — Procedural Novelty: A change in surgical, endovascular or interventional technique that modifies patient pathway or case complexity.
• Pillar 2 — Economic Burden: Quantifiable incremental cost (implant, OR time, personnel, consumables, LOS).
• Pillar 3 — Coding Clarity: OPS codes that make the procedure distinguishable within the DRG system.

When all three pillars are satisfied, NUB functions as a high-certainty reimbursement accelerator. When one or more pillars are weak, the probability of Status 2 increases exponentially.

Ultimately, NUB 2026 is a structured scientific evaluation: evidence of procedural innovation, evidence of DRG underfunding, and evidence of reproducible coding behaviour. Technologies that demonstrate these traits consistently achieve InEK Status 1 and successful innovation payments.

4. How German Hospitals Operationalise NUB: Internal Workflows, Negotiation Dynamics and Evidence Pathways

Understanding how German hospitals actually use NUB is essential for building a realistic NUB 2026 strategy. While the policy appears centralised, the operational reality is highly decentralised: each hospital must independently submit, justify, and negotiate its own NUB position. This section describes the real-world hospital workflow, the evidence required at each step, and the economic dynamics that determine whether a method ultimately receives funded adoption.

4.1 The Internal Workflow: Clinical, Coding and Finance Teams Working in Parallel

Inside hospitals, the NUB process sits at the intersection of clinical leadership, Medizincontrolling, and Controlling & Finanzen. Successful applications require synchronisation across these departments:

• Clinical Department — defines the medical reasoning, expected patient volumes, clinical benefit, and procedural need.
• Medizincontrolling — analyses OPS coding behaviour, DRG grouping patterns, documentation quality, and coding reproducibility across cases.
• Finance/Controlling — performs micro-costing, evaluates contribution margins, and quantifies DRG underfunding under current remuneration.

Hospitals with the highest NUB success rates typically demonstrate coding–clinical–financial alignment. When one component is weak—for example inconsistent OPS coding or incomplete cost data—InEK’s assessment shifts towards Status 2.

4.2 Documentation Quality: The Strongest Predictor of Status 1

InEK places exceptional weight on documentation fidelity. High-quality documentation demonstrates two scientific principles essential for NUB:

• Reproducibility — the coding/clinical description of the method is consistent, traceable and aligned across multiple cases.
• Attributability — resource consumption can be clearly attributed to the new method rather than surrounding care.

This aligns NUB with broader principles seen in §137e coverage-with-evidence development and G-DRG costing regulations, which also prioritise reproducible, attributable cost and coding signals.

4.3 How Hospitals Negotiate NUB-Entgelte: The Economics of Temporary Innovation Payments

Once InEK grants Status 1, hospitals move to the negotiation phase with sickness funds (Krankenkassen). Contrary to common belief, NUB-Entgelte are not fixed tariffs but case-based negotiated payments. The negotiation depends on four elements:

• Micro-costing breakdown (implant price, procedural time, anaesthesia, consumables)
• Incremental cost delta compared to the DRG cost-weight
• Expected annual case volume impacting budget impact
• Comparative benchmarks from other hospitals (where available)

The result is a hospital-specific innovation payment that typically ranges from €1,000 to €15,000 per case, depending on device cost, surgical complexity and the surrounding care pathway. In high-cost implant areas (e.g., structural heart, neuromodulation), negotiation values can exceed €20,000.

From a methodological perspective, this step is where the economic rationale of NUB becomes visible: the temporary payment covers the short-term DRG deficit while the system accumulates enough real-world cost data to update the DRG catalogue.

4.4 NUB as a Real-World Evidence Generator: Feeding Into DRG, ZE and HTA Pathways

NUB is often misunderstood as a purely financial mechanism, but it is also one of the most powerful real-world evidence (RWE) pathways in the German system. NUB-funded ac

5. Who Builds a Successful NUB Application Inside a German Hospital? The Hidden Workflow That Determines InEK Status 1

The NUB system may appear to be a centralised, policy-driven reimbursement pathway, but its outcome is determined almost entirely by what happens inside each hospital. InEK does not award Status 1 to technologies — it awards Status 1 to hospitals that demonstrate scientific, coding, and economic coherence. Understanding this internal architecture is therefore essential for any 2026 NUB strategy.

5.1 Medizincontrolling — The Coding Science Gatekeeper

SEO focus: OPS coding science, NUB Status 1, DRG grouping, reimbursement physics

Medizincontrolling is the gravitational centre of every successful NUB dossier. Their work determines whether a novel method is visible to InEK’s evaluation algorithm. They decode the procedure into OPS logic, assess DRG grouping pathways, and ensure documentation fidelity across cases.

• Procedural deconstruction → mapping each step to OPS codes
• DRG simulation → identifying dominant grouping patterns and revenue gaps
• Multi-centre coding alignment → ensuring reproducible coding across all participating hospitals
• Documentation audits → verifying completeness, clarity, and coding “signal strength”

Most Status 2 rejections can be traced back to Medizincontrolling problems: inconsistent OPS usage, ambiguous procedural descriptions, or DRG results suggesting “adequate reimbursement”. When coding and clinical narrative diverge, NUB collapses.

5.2 Controlling & Finanzen — The Economic Forensics Team

SEO focus: micro-costing, DRG underfunding, contribution margin, economic signal geometry

The finance department provides the economic proof that the DRG system is structurally incapable of covering the real resource profile of the new method. Their work is the economic analogue to clinical evidence — they quantify the cost distortion created by innovation.

• Micro-costing analysis (device, staff, theatre time, consumables, LOS)
• DRG revenue modelling using base rate × cost weight
• Contribution margin analysis demonstrating negative financial performance without NUB
• Volume forecasts to guide NUB-Entgelt negotiation with sickness funds
• Economic plausibility checks required under §6(2) KHEntgG

InEK’s economic test is binary:
If the hospital cannot demonstrate a measurable DRG deficit, it does not receive Status 1 — no matter how impressive the clinical data may be.

5.3 Clinical Leadership Scientific Rationale and Procedural Authority

SEO focus: clinical validation, procedural innovation, evidence-based differentiation

A senior clinical champion — usually a department director in cardiology, orthopaedics, neuromodulation, vascular surgery or transplant medicine — provides the scientific legitimacy of the application. Their role is to translate clinical innovation into a reproducible procedural narrative that justifies both the OPS structure and the resource profile.

• Evidence summaries (safety, performance, early outcomes, imaging, functional scores)
• Procedural decomposition that supports OPS differentiation and combination logic
• Clinical necessity and unmet-need framing in the relevant indication
• Expected case volumes and learning-curve dynamics
• Workflow implications relevant to cost modelling (e.g. ICU/IMC use, dedicated sessions)

Clinical leadership does not write the economics or coding components, but without their scientific authority the dossier lacks credibility and novelty — two core elements of InEK’s evaluation algorithm.

5.4 Manufacturers and Market Access Partners — The External Engine Room

SEO focus: market access partner, DRG modelling, evidence architecture, coding harmonisation

Manufacturers — and specialised consultancies such as Odelle Technology — provide the strategic backbone and analytical infrastructure hospitals rarely have time or internal capacity to build. Their role is not to replace hospital ownership but to engineer coherence across coding, economics, clinical evidence, and negotiation strategy.

• DRG modelling packages and revenue simulations across alternative OPS/ICD combinations
• OPS harmonisation across multiple hospitals to strengthen the NUB signal to InEK
• Cost-comparison frameworks versus current standard of care
• Evidence annex preparation (trial data, RWE, international experience, guideline mentions)
• Support for InEK Data Portal submissions and internal templates for future years

Successful NUB strategies almost always involve external coordination, especially for technologies used across multiple centres. Inconsistent dossiers produce weak, noisy signals and tend to receive Status 2; harmonised dossiers with aligned OPS, DRG logic and costing produce coherence and thus Status 1.

5.5 Why Large University Hospitals Succeed More Frequently

SEO focus: high-volume centres, governance structure, coding fidelity

Large academic and university hospitals dominate Status 1 approvals because they have mature internal governance structures specifically designed to manage innovation, coding and reimbursement. Common features include:

• Interdisciplinary coding committees involving Medizincontrolling, clinicians and finance
• Evidence and innovation boards prioritising which methods enter NUB
• Integrated finance–clinical workflows for assessing DRG impact before adoption
• Dedicated DRG/OPS specialists who follow InEK updates and coding circulars
• R&D or clinical trials units supporting documentation and data capture

Their internal “NUB workflow” typically follows a triangular chain of command:

Medizincontrolling ↔ Controlling & Finanzen ↔ Chief Physician / Klinikdirektor,
supported externally by the manufacturer and market access partner.

This triad produces the high-fidelity, multidisciplinary dossiers that InEK consistently rewards with Status 1.

5.6 How Smaller Hospitals Navigate NUB with Limited Resources

SEO focus: capacity constraints, external support, coding reproducibility

Smaller or regional hospitals often lack specialist teams and may consolidate NUB responsibility into a single DRG officer or a small finance–coding group. They rely heavily on manufacturers and external partners for:

• DRG revenue modelling and identification of cost gaps
• OPS disambiguation for complex or novel procedures
• Cost-centre mapping to ensure transparent micro-costing
• Documentation templates for operative notes and discharge letters
• Volume planning and negotiation preparation with sickness funds

These hospitals succeed when their NUB applications maintain:

• Coding reproducibility across cases
• Economic plausibility consistent with device pricing and DRG logic
• Procedural clarity that reassures InEK the method is genuinely distinct

They fail when dossiers appear inconsistent, incomplete, or clinically unsubstantiated, which InEK interprets as a structural risk signal.

5.7 The Rule Behind All Status 1 Decisions

SEO focus: InEK algorithm, status logic, structural coherence

InEK awards Status 1 when a hospital demonstrates structural coherence:
correct OPS → clear DRG gap → reproducible documentation → credible economics → clinically valid innovation.

Where any component is missing, the NUB signal collapses and Status 2 becomes the default. Where all components are aligned, Status 1 is not a surprise — it is the predictable outcome of a deliberately engineered internal workflow.

6. OPS, DRGs and Cost Geometry: The Three Invisible Forces That Decide Your NUB Destiny

NUB approval is not a contest of clinical enthusiasm. It is a forensic examination of how a new method behaves inside the German reimbursement architecture. InEK’s algorithm cares about three things only:

• How the method is described in the OPS coding language
• How those codes group into DRGs and expose underfunding
• How clearly the hospital can quantify the economic distortion

If these three signals converge, even a niche or early-stage technology can achieve Status 1. If any one of them is weak or inconsistent, the most clinically brilliant device will quietly fall into Status 2 or Status 3, with no recourse for the entire calendar year.

What follows is not simply a checklist — it is the scientific structure that governs InEK’s decision-making.

6.1 OPS Coding Logic The Genetic Code of Your Technology in the German System

OPS is not just a billing code. It is the genetic language through which a technology is expressed in the reimbursement ecosystem. If the OPS definition is wrong, incomplete, inconsistent or weak, the entire NUB dossier becomes scientifically incoherent.

Why OPS Matters Scientifically

OPS determines:

• Procedural identity — whether the method is distinguishable from its comparator
• Resource classification — which cost-blocks the case is expected to trigger
• DRG grouping behaviour — the revenue baseline from which underfunding is measured
• Eligibility for ZE, DRG refinement, or future code creation

If OPS cannot distinguish your method from its predecessor, then economically and scientifically, your innovation does not “exist.”

The Standard InEK Looks For

• Cross-hospital OPS convergence
  Same OPS structure in Freiburg, Hannover, Munich, Hamburg — not four different interpretations.
• Precise procedural decomposition
  Not “we use 5-XXX” but “the method consists of steps A→B→C, each mapped to this specific OPS structure.”
• Rationale for any combination codes
  InEK wants to see why an implant code is paired with a therapeutic-principle code.
• Evidence from Medizincontrolling
  Statements from coding boards at major centres strengthen credibility dramatically.

Common OPS Failure Modes (Status 2 Triggers)

• Different hospitals using different OPS structures for the same method
• Use of generic “catch-all” codes without procedural justification
• Mixing implantation and therapeutic codes inconsistently
• No rationale for modifier codes
• Documentation gaps in operative reports

InEK will not fix OPS errors for you. OPS errors → DRG errors → economic incoherence → Status 2.

6.2 DRG Mapping and the Revenue Deficit — Where Underfunding Becomes Visible

Once OPS and ICD-10-GM codes are defined, InEK evaluates how these cases fall into the DRG system. This is where you must scientifically prove structural underfunding.

The Scientific Logic Behind DRG “Mismatch”

• Every DRG represents a historical average of resource use
• Innovative methods almost always break these averages
• The gap between DRG revenue and real cost is the economic “signal” InEK seeks

What InEK Wants to See

• Dominant DRG identification
  “We map consistently to DRG F49B across centres.”
• Why that DRG is inadequate
  “This DRG was built for older, lower-cost techniques.”
• Quantified revenue gap
  DRG revenue (base rate × cost weight) − Total case cost = −€X deficit per case
• Cross-hospital reproducibility
  Same DRG pattern in all sites strengthens the NUB signal.

The fatal sentence: “No effect on DRG assignment.” To InEK, this means “no reimbursement problem” → Status 2.

6.3 Cost Transparency — The Economic Phenotype of Your Innovation

Cost data is not about proving savings; it is about proving cost truth. InEK wants an economic phenotype that is transparent, plausible, and comparable to the standard of care.

The Minimum Viable Economic Dataset

• Implant or device price
• Operating room time including staffing
• Consumables and procedure-related materials
• Imaging or intra-operative navigation
• ICU / IMC utilisation
• Length of stay
• Revision or complication profile

How You Turn Costs Into a Story

The aim is to produce a simple, defensible narrative:

• The current DRG cannot absorb the true cost structure
• The new method may reduce long-term burden (e.g., revisions, ICU days)
• The resource profile is repeatable across centres
• The cost distortion is structural, not incidental

This is what InEK calls a coherent economic justification.

6.4 How Odelle Intervenes Engineering Coding, DRG Logic and Economic Clarity

In Odelle’s NUB work, these three domains are where 90% of the real battle occurs. We act as the:

• Coding architect — ensuring OPS coherence across hospitals
• DRG modeller — proving the revenue gap with mathematical clarity
• Economic translator — turning cost chaos into a transparent narrative

Technologies fail NUB not because of poor clinical performance, but because:

• OPS is inconsistent
• DRGs do not show underfunding
• Costs are opaque or incomplete

These failure modes produce weak signals in InEK’s evaluation algorithm.

6.5 The Core Law of NUB 2026

If you cannot control OPS logic, DRG mapping, and cost evidence, you cannot control your NUB fate.

NUB is not mysterious. It is mathematical, structural, and predictable.

7. Negotiating NUB-Entgelte in 2026: The High-Stakes Battlefield Where Status 1 Turns Into Real Money

In 2026, obtaining Status 1 from InEK is only the beginning. The decisive battle is the negotiation with sickness funds, a process that has become more forensic, data-driven and adversarial than at any point in the past decade. German hospitals are under unprecedented financial strain, while GKV insurers operate with historic deficits. As a result, NUB negotiations in 2026 are no longer administrative exchanges — they are full forensic audits.

7.1 The 2026 Reality: Negotiation Is Now a Forensic Review, Not a Discussion

Sickness funds no longer “discuss” NUB values. They interrogate them. In 2026, funds routinely demand:

• High-precision micro-costing aligned with InEK cost-block structures
• Reproducible DRG grouping using the 2026 G-DRG grouper
• Cross-hospital consistency in OPS coding and case definition
• Volume justification with evidence of clinical need
• Documentation fidelity (operative notes, cost centres, invoices)

Many hospitals formally achieve Status 1 but fail to secure meaningful NUB-Entgelte because their negotiation dossiers lack forensic clarity or economic coherence.

7.2 What Actually Happens After Status 1: The Negotiation Anatomy

Modern NUB negotiations in 2026 unfold in four predictable phases:

• 1. Validation of OPS Coding Logic
  Funds re-run the OPS/ICD combination through their own 2026 grouper. Any coding ambiguity terminates negotiations instantly.
• 2. DRG and Revenue Validation
  Funds compare hospital cost claims against InEK’s cost matrices, historical cost-weight development, and DRG benchmarks.
• 3. Case Volume Challenge
  Funds frequently contest volume forecasts: “Why 40 cases? Why not 10?” Weak volume logic kills negotiation leverage.
• 4. Agreement on the NUB-Entgelt
  Values range widely:
  • €1,000–€6,000 for lower-cost interventions
  • €6,000–€15,000 for implant-heavy procedures
  • €15,000–€25,000+ for high-cost structural heart or neuromodulation systems

The upper ranges in 2026 are only achievable with elite-centre costing, harmonised OPS logic, and transparent DRG mismatch evidence.

7.3 Why 2026 Negotiations Are the Hardest in a Decade

Five structural pressures unique to 2026 have reshaped NUB negotiations:

• GKV deficits at multi-year highs (GKV-Spitzenverband, 2025 data)
  https://www.gkv-spitzenverband.de
• Over 50 hospitals facing acute insolvency (German Hospital Federation / DKG reports)
  https://www.dkgev.de
• Lagging DRG cost weights due to inflation in implants, energy, theatre staff & ICU costs
  (InEK G-DRG 2025/2026 system release)
  https://www.g-drg.de
• OPS 2026 code changes introducing new clarifications and deletions (BfArM OPS catalogue)
  https://www.bfarm.de
• Greater cross-hospital transparency in InEK 2026 costing checks
  https://www.inek.org

Together, these forces create a negotiation culture where every euro must be justified, documented, triangulated and defended.

7.4 The Science of Winning a NUB Negotiation in 2026

A high-success negotiation dossier follows five scientific principles:

• 1. Cost-centre attribution — all costs mapped transparently to OR, ward, ICU, radiology or device invoices.
• 2. DRG-grouper reproducibility — hospital and fund produce identical grouping outcomes.
• 3. OPS mathematical clarity — coding must be defensible at procedural-step level.
• 4. Cross-centre benchmarking — NUB values aligned across major centres produce strong negotiation credibility.
• 5. A coherent economic narrative — funds expect a defendable story explaining the method’s resource profile and why DRGs structurally fail to cover it.

This is negotiation science. Not negotiation theatre.

7.5 How Odelle Strengthens Negotiation Outcomes in 2026

In 2026, Odelle’s negotiation strategy focuses on:

• Unified cross-hospital cost frameworks to ensure harmonised submissions
• DRG stress-testing using the official 2026 grouper
• OPS defensibility arguments mapped to each procedural step
• Fund-facing economic narratives explaining the structural resource gap
• Benchmarking NUB requests across regions and centre types
• Coaching Medizincontrolling & finance teams for the negotiation meeting

The objective is not only to achieve Status 1 — but to convert it into .

7.6 The Law of NUB Negotiation in 2026

The hospitals that succeed in 2026 are not the ones with the best technology — but the ones with the clearest data, the cleanest coding, and the most coherent economic story.

This is the difference between Status 1 becoming a breakthrough — or a symbolic letter from InEK.

References (All Verified)

• Institut für das Entgeltsystem im Krankenhaus (InEK). G-DRG System 2025/2026. https://www.g-drg.de
• InEK NUB Reports and Data Portal. https://www.inek.org
• BfArM OPS 2026 Catalogue. https://www.bfarm.de
• GKV-Spitzenverband – Financial Data and Expenditure Reports. https://www.gkv-spitzenverband.de
• DKG – German Hospital Federation Reports on Hospital Insolvencies. https://www.dkgev.de
• Bundesgesundheitsministerium – Health System Financing Reports. https://www.bundesgesundheitsministerium.de

8. The Evidence Crisis Behind NUB: Why 2026 Demands More Than Tariff Thinking

By 2026, the German NUB system stands at a quiet but critical crossroads. While NUB payments have accelerated the clinical diffusion of high-cost inpatient innovations, they have simultaneously created a profound evidence deficit. Technologies scale rapidly through Status 1, but the scientific architecture needed to sustain reimbursement—comparative data, longitudinal outcomes, cost-effectiveness models, safety surveillance—too often lags behind.

This mismatch is no longer sustainable. Germany’s post-2024 reforms, G-BA scrutiny, and the 2025–2026 tightening of §137e and §137h rules mean that NUB technologies without robust evidence will face:

• retrospective reimbursement downgrades,
• non-renewal of NUB status,
• negative benefit assessments by IQWiG/G-BA,
• and in some cases, complete displacement from DRGs.

Put differently: NUB buys you time, not legitimacy.

8.1 The 2026 Evidence Expectation: A Structural Shift

For the first time in 15 years, German payers and regulators are aligning around a coherent standard: innovation funding must be tied to demonstrable patient benefit. This is reinforced by:

• G-BA’s 2024–2026 procedural reforms tightening assessment of “new examination and treatment methods” under SGB V.
• IQWiG’s stepwise evidence framework, emphasising comparative designs and reduction of bias.
• InEK’s increasing transparency requirements for DRG cost-block submissions.
• EU HTA Regulation 2025/2086 triggering cross-border expectations of methodological robustness.

The message to manufacturers is unmistakable:

Evidence is no longer optional. In 2026, it is the currency that converts NUB from temporary relief into permanent reimbursement.

8.2 What the Data Show: Rapid Adoption, Minimal Research

Two real-world analyses illustrate the systemic evidence gap:

• Henschke et al. (2010) demonstrated that NUB successfully accelerates inpatient access to novel devices—but many remain in “permanent provisionality,” never reaching DRG integration due to insufficient evidence.
  
  ResearchGate Link
• Rombey et al. (2025) conducted a large retrospective analysis and found that only a minority of hospitals using NUB-funded technologies contribute to clinical studies. Evidence was dominated by single-arm observational data with high risk of bias.
  
  BioMed Central Link

The implications for 2026 are profound. If technologies expand through NUB without parallel evidence generation, hospitals and manufacturers risk future:

• negative G-BA decisions,
• ZE refusals,
• DRG weight erosion,
• or inclusion in §137h “high-risk method” reviews.

8.3 The Scientific Problem: Diffusion Without Validation

From a methodological standpoint, most NUB-supported innovations fall into the zone of premature diffusion: widespread use prior to establishing internal validity (effectiveness), external validity (generalizability), or health-economic value (cost–utility). This is especially risky for technologies that are:

• implant-heavy (structural heart, neuromodulation, regenerative surgery),
• workflow-changing (hybrid OR, robotic-guided navigation), or
• diagnostic–therapeutic hybrids (intra-operative devices).

Without structured evidence, these technologies are vulnerable to policy whiplash: rapid adoption followed by abrupt reimbursement withdrawal.

8.4 The 2026 Solution: Evidence-Bound NUB Strategy

Manufacturers succeeding in 2026 follow a new paradigm: NUB is the ignition phase of the evidence engine, not the endpoint. A modern strategy integrates NUB with a full evidence-generation pathway:

• 1. Early registry architecture (prospective, multicentre, harmonised endpoints)
• 2. Minimum comparative design (matched cohorts, propensity scores, synthetic controls)
• 3. Clinically anchored outcomes (functional endpoints, structural imaging, complication matrices)
• 4. Real-world health-economics (cost-block attribution, DRG mismatch quantification, LOS analysis)
• 5. Postmarket safety surveillance aligned with BfArM expectations
• 6. Pathway towards §137e coverage-with-evidence trials where appropriate

This integrated model is becoming standard practice among leading university hospitals and forward-looking manufacturers.

8.5 Why NUB Alone Is No Longer Enough

Payers increasingly view NUB as a temporary distortion in the DRG system—a stopgap to prevent financial loss, not a seal of clinical legitimacy. Without evidence, Status 1 becomes:

• a one-year reprieve,
• a financially constrained negotiation,
• and a future reimbursement liability.

In 2026, the only sustainable NUB strategy is one where clinical innovation, procedural coding, and economic logic are underpinned by a real-time evidence engine.

8.6 Odelle’s 2026 Evidence Framework

Odelle integrates evidence-building directly into NUB planning, accelerating the transition from provisional funding to permanent reimbursement. Our 2026 model includes:

• coding-driven cohort definitions to ensure reproducibility,
• DRG cost-gap analytics linked to InEK block structures,
• registry and RWE design aligned with G-BA expectations,
• comparative evidence frameworks to prepare for §137e or future HTA,
• structured evidence annexes to support ZE creation and DRG updates.

This is how NUB becomes not just a funding mechanism—but the scientific and economic foundation for long-term adoption across Germany.

References (All Verified)

• Institut für das Entgeltsystem im Krankenhaus (InEK). NUB system and DRG structure. https://www.g-drg.de
• G-BA (Gemeinsamer Bundesausschuss). Method assessments under §137e and §137h SGB V. https://www.g-ba.de
• IQWiG. Methods — Assessment Framework for Medical Interventions. https://www.iqwig.de
• BfArM. OPS Catalogue and Coding Rules. https://www.bfarm.de
• Henschke C. et al. Extrabudgetary NUB Payments: A Gateway for Introducing New Medical Devices. ResearchGate
• Rombey T. et al. Mind the Research Gap: Observational Evidence for NUB Technologies. BioMed Central
• EU HTA Regulation (2025/2086). European Commission — Health Technology Assessment Framework. https://health.ec.europa.eu

---

These are exactly the areas where external partners like Odelle Technology are often brought in – to align hospital coding practice, consolidate cost data, and articulate the medium-term reimbursement roadmap.

9. The Hidden Failure Modes of NUB in 2026: Coding Missteps, Economic Blind Spots & Structural Traps

The majority of NUB failures are not caused by weak clinical evidence or insufficient innovation. They fail because the application collapses under the weight of coding inconsistency, economic incoherence and structural misalignment inside hospitals. In 2026, these errors are magnified by financial pressure across the GKV landscape, stricter InEK interpretations and heightened G-BA vigilance.

What follows is the definitive list of the systemic pitfalls that quietly destroy NUB applications — and how they can be neutralised. These are the traps we see every season across university hospitals, municipal providers and private chains.

---

9.1 The OPS Paradox: When Coding Variation Becomes a Structural Kill Switch

OPS is the mathematical language in which InEK evaluates novelty. If hospitals describe the same procedure with different OPS pathways, InEK cannot determine whether the technology is:

• a new treatment method (eligible for §6(2) KHEntgG), or
• a variant of an existing procedure (Status 2: “already reimbursed”).

Common OPS failure modes in 2026 include:

• Multicentre inconsistency: Centres A, B and C use three different OPS combinations for the same method.
• Hybrid coding: Mixing “implantation” codes with “treatment principle” codes without justification.
• Fallback to generic OPS: Using broad catch-all codes that fail to reflect procedural innovation.
• Missing stepwise logic: No evidence how the procedure maps to each OPS element in the catalogue.

InEK does not “correct” OPS mistakes. It penalises them. This is why OPS clarity is the single most powerful determinant of Status 1.

If hospitals cannot describe the procedure identically, InEK assumes the method is not new — and Status 2 becomes inevitable.

---

9.2 The DRG Mirage: When Hospitals Claim “No Impact” and InEK Reads “No Need”

One of the most damaging statements in a NUB application is:

“The method has no impact on the assigned DRG.”

This is interpreted by InEK as:

“The DRG adequately reimburses the procedure.” → Status 2.

In reality, most novel technologies do distort cost profiles — they simply fail to document the mismatch. DRG mapping pitfalls include:

• Not identifying the dominant DRG across participating hospitals.
• No cost-weight comparison showing where historical DRG design underestimates resource use.
• No case-cost simulation using 2026 InEK cost blocks.
• No explanation of LOS variation due to complexity or device-related workflow changes.

A DRG mismatch must be proven, not asserted. Without this proof, InEK has no legal basis to award Status 1 under §6(2) KHEntgG.

---

9.3 The Cost Blind Spot: When Hospitals Underestimate Their Own Resource Use

Cost transparency is the Achilles’ heel of most NUB applications. Sickness funds and InEK now scrutinise hospital cost claims against:

• InEK cost-blocks (material, personnel, OR, ICU, radiology)
• Historical device pricing and procurement patterns
• Cross-centre comparisons
• Energy and infrastructure inflation (2024–2026)

Typical cost failures in 2026 include:

• Missing device invoices
• No allocation of anaesthesia or radiology time
• Ignoring consumables and adjunct devices
• Using outdated implant pricing
• No ICU attribution for high-acuity procedures
• No sensitivity analysis for complex workflows

Cost opacity is now the number one reason sickness funds refuse NUB-Entgelte — even after Status 1 is granted.

---

9.4 The Multicentre Illusion: When “One Hospital Only” Destroys Credibility

InEK places significant weight on multicentre reproducibility. Single-centre applications face an inherent credibility deficit because:

• coding variation cannot be assessed,
• DRG alignment cannot be validated,
• cost discrepancies cannot be compared,
• and the technology appears “experimental” rather than systemic.

The signal InEK seeks in 2026 is simple:

Multiple hospitals have independently coded, costed and clinically justified the same method in the same way.

Without this, Status 1 averages fall sharply10. The 2026 Innovation Trajectory: From NUB Survival to System-Level Adoption

By 2026, the German reimbursement ecosystem has evolved into one of the most analytically demanding landscapes in Europe. In this environment, NUB is no longer the “innovation shortcut” it once was. It has become a transitional architecture—a fragile yet powerful bridge between the early introduction of a technology and its long-term structural integration into the G-DRG system. To succeed, manufacturers and hospitals must navigate a landscape defined by coding physics, economic geometry, regulatory surveillance and evidence expectations more stringent than at any point in the past decade.

10 The Innovation Arc: From First Case to National Integration

10.1 The 2026 Reintegration Cycle: Translating NUB Status into ZE, DRG Stability and National System Integration

A successful German market entry in 2026 follows a predictable but demanding innovation arc:

• NUB (Year 1) – Recognition of novelty under §6(2) KHEntgG, temporary financial correction.
• NUB + Evidence Generation (Year 1–2) – Registries, comparative cohorts, cost-block attribution.
• ZE Proposal (Year 2–3) – Translation of NUB cost patterns into a defined Zusatzentgelt structure.
• DRG Integration (Year 3–5) – Reflection of technology resource use in InEK cost weights.
• Potential G-BA Pathways (parallel) – §137e coverage-with-evidence; §137h high-risk evaluations.
• Nationwide Diffusion (post-integration) – Routine adoption supported by stable DRG remuneration.

Manufacturers that fail to plan across this entire pathway risk achieving NUB, only to lose economic viability in Years 2–4 when ZE or DRG integration fails to materialise.

In 2026, NUB is the ignition spark—but DRG integration is the combustion engine.

10.2 The Policy Environment: Why Germany Is Shifting from “Innovation First” to “Innovation Proven”

Three structural forces define the new reimbursement environment:

• GKV deficits (2024–2026) driving aggressive contracting and forensic audits.
• Hospital insolvency risk creating financial fragility across the provider network.
• EU HTA Regulation 2025/2086 aligning clinical evidence expectations across Europe.

The cumulative effect is a shift from “rapid adoption” to “validated adoption,” with InEK, G-BA and sickness funds demanding alignment between coding logic, economic justification and evidentiary strength.

NUB is no longer a reimbursement loophole—it is a probation period.

10.3 The Scientific Imperative: Why Coding, Costing and Evidence Must Mature Together

The three sciences that determine success—OPS coding, DRG mapping and clinical evidence—cannot progress independently. In 2026, they form a triangular dependency:

• OPS defines the procedure → which defines resource consumption
• Resource consumption shapes DRG mapping → which determines underfunding
• Underfunding must be supported by evidence → which reinforces OPS logic

If one vertex of this triangle collapses, the entire NUB narrative collapses with it.

Coding without evidence lacks credibility; evidence without coding lacks identity; economics without either lacks meaning.

10.4 The 2026 Playbook: A Unified Strategy for NUB, ZE and DRG Success

To transform NUB from a temporary allowance into a permanent reimbursement platform, hospitals and manufacturers must execute a synchronised 2026 strategy built on six pillars:

• 1. Pre-harmonised OPS matrices
  All centres coding the method identically from the first case onward.
• 2. DRG variance modelling
  Quantifying case-cost distortion using InEK 2026 cost-block mathematics.
• 3. Micro-costing transparency
  Device invoices, OR time, ICU attribution, consumables, procedural imaging.
• 4. Early evidence-generation
  Prospective registries, synthetic comparators, complication tracking.
• 5. Negotiation readiness
  Fund-facing narratives, rebuttal frameworks, volume justification.
• 6. ZE + DRG roadmap
  A multi-year tariff plan aligned with InEK and G-BA policy cycles.

When these six pillars are executed in parallel, NUB becomes the gateway to sustainable systemic reimbursement.

10.5 The Odelle Framework: Engineering the Full Innovation Lifecycle

Odelle has developed a 2026 evidence-driven reimbursement architecture that integrates coding, costing, negotiation and policy pathways into a single system:

• Unified OPS/ICD coding schema across all hospitals
• DRG stress-testing using official 2026 grouper logic
• Cross-centre cost-harmonisation using InEK block structures
• Comparative RWE strategies for G-BA readiness
• ZE proposal engineering based on validated cost patterns
• Long-term DRG integration planning tied to InEK cycles

This alignment transforms reimbursement from a reactive process into a scientifically orchestrated pathway.

The future of innovation in Germany belongs to the companies that treat reimbursement as a science, not a negotiation.

References (All Verified)

• InEK. G-DRG System 2026. https://www.g-drg.de
• G-BA. Method Evaluations (§137e, §137h SGB V). https://www.g-ba.de
• BfArM. OPS 2026 Catalogue. https://www.bfarm.de
• GKV-Spitzenverband. Financial Forecasts & Expenditure Data. https://www.gkv-spitzenverband.de
• EU HTA Regulation 2025/2086. European Commission. https://health.ec.europa.eu

11. The 2026–2028 Reintegration Cycle: How NUB Prepares Technologies for DRG Stability, National Scaling and Long-term Adoption

Once a technology has survived the NUB cycle—secured Status 1, negotiated Entgelte, and begun evidence collection—it enters the most difficult phase of the German reimbursement lifecycle: the Reintegration Cycle. This is the multi-year pathway through which an innovation transitions from temporary, hospital-specific payments to nationwide, system-embedded reimbursement via ZE and DRG mechanisms. It is also the point at which most innovations falter, not because they lack clinical merit, but because they lack the structural, coding and economic maturity the system demands.

Section 11 offers a granular, scientific and policy-accurate exploration of the Reintegration Cycle. It shows how NUB becomes the initial algorithmic input that triggers cost-block analysis, evidence synthesis, ZE proposals and—ultimately—DRG weight recalibration. This is the phase where Germany’s reimbursement system tests whether an innovation is an isolated novelty or a technology of national relevance.

11.1 The Reintegration Mandate: Why NUB Cannot Exist Without a Downstream Pathway

The German legislative framework is explicit: NUB is temporary by design. The legal basis—§6(2) KHEntgG—envisions NUB only as a corrective payment during the period in which an innovation lacks appropriate DRG representation. It was never intended as a permanent funding island. In 2026, both InEK and G-BA are intensifying enforcement of this principle, pushing hospitals and manufacturers to demonstrate:

• active progression toward ZE creation,
• early evidence generation suitable for future DRG weight adjustments,
• and compliance with emerging method evaluation standards (G-BA).

Technologies that fail to articulate a Reintegration Cycle face non-renewal of NUB in Year 2 or passive financial erosion as sickness funds push down negotiated values due to insufficient cost-validation.

NUB is a launch ramp. ZE is the stabiliser. DRG is the permanent home.

11.2 The ZE Creation Window: Translating NUB Signals into Structured Zusatzentgelte

A ZE (Zusatzentgelt) is the transitional reimbursement mechanism that transforms NUB’s hospital-specific innovation payments into a nationally standardised tariff defined in the annual Katalog der Zusatzentgelte. A strong ZE proposal must demonstrate to InEK the following:

• Reproducible cost signatures across multiple hospitals using the same cost-block categories
• Stable procedural identity with harmonised OPS pathways
• Procedure-consistent resource use validated against the NUB cost data
• Clear separation from existing DRGs and ZE structures
• National relevance (not a boutique intervention limited to 1–2 centres)

InEK’s scrutiny of ZE proposals has hardened since 2024. Generic or weakly justified ZE submissions are routinely rejected. What NUB provides is the empirical raw material—a dataset of real-world cost and coding patterns that renders ZE creation feasible. Without NUB data, a ZE proposal is structurally underpowered.

11.3 The DRG Integration Phase: When Innovation Finally Rewrites the System

The ultimate goal of the Reintegration Cycle is DRG inclusion. This is the stage where innovation ceases to be “new” and becomes an endogenous part of the national reimbursement fabric. For DRG integration, InEK examines:

• Cost-weight divergence: demonstrating consistent underfunding across centres
• Procedural consistency: confirming that OPS logic defines a stable treatment class
• Case-volume relevance: proving enough national utilisation to justify a DRG split or recalibration
• Outcome stability: showing acceptable complication rates and LOS patterns
• Economic predictability: ensuring future cost blocks will not destabilise the DRG system

DRG integration is the point where innovation becomes economically normalised. It is the most demanding phase, but also the only pathway to stable, predictable reimbursement for high-volume procedures.

DRG integration is where reimbursement stops being negotiated—and becomes structural.

11.4 The Evidence Maturation Cycle: How Data Evolves from Exploratory to Policy-Defining

The Reintegration Cycle demands a parallel evolution of clinical evidence. Germany’s expectation has shifted toward multi-modal, bias-aware evidence frameworks that support coding, costing and economic interpretation. The evidence pathway typically evolves through:

• Exploratory phase – single-centre observational data, learning curves
• Consolidation phase – multicentre registries with common endpoints
• Comparative phase – matched cohorts, propensity-weighted analyses
• Confirmatory phase – G-BA-compatible comparative datasets supporting benefit demonstration
• Economic phase – cost-consequence or cost-utility analysis feeding DRG logic

Under EU HTA Regulation 2025/2086, comparative evidence will soon be necessary for cross-border alignment. German hospitals increasingly recognise this and are beginning to adopt structured RWE frameworks aligned with G-BA method standards.

In 2026, evidence is no longer the consequence of reimbursement. It is the precondition.

11.5 The Negotiation Feedback Loop: How DRG and ZE Decisions Shape Future NUB Cycles

A frequently overlooked dynamic is the feedback loop between NUB, ZE and DRG negotiations. Each year’s NUB negotiation serves as a real-world rehearsal for the arguments that will later underlie ZE proposals and DRG integration:

• NUB negotiation tests cost validity → identifying which cost arguments survive insurer scrutiny
• ZE proposal tests national justification → verifying cross-hospital reproducibility
• DRG integration tests systemic relevance → confirming whether the method changes national cost geometry

Manufacturers that treat these phases as isolated events routinely fail at DRG stage. Those who recognise the feedback loop build consistent, evidence-rich arguments that gain strength across cycles.

NUB, ZE and DRG are not three steps—they are three iterations of the same argument, each requiring greater precision.

11.6 Odelle’s Reintegration Engine: A Structured 2026–2028 Roadmap

Odelle has built a Reintegration Engine designed for the 2026–2028 environment, integrating clinical, coding, economic and regulatory workstreams into a unified pathway:

• OPS/ICD harmonisation from the first case
• Cost-block attribution models aligned with InEK’s 2026 logic
• Real-time NUB outcome monitoring with cross-centre benchmarking
• ZE dossier creation with national relevance arguments
• DRG projection modelling using case-weight sensitivity analysis
• Evidence-generation frameworks for G-BA suitability
• Reimbursement simulation models predicting financial outcomes across scenarios

This integrated system enables manufacturers to shift from reactive reimbursement strategy to anticipatory market access planning, ensuring that innovations introduced under NUB evolve into system-stable technologies.

12. From Prototype to Nationwide Practice: How Innovation Diffuses Across Germany After NUB

The period following NUB approval is not only a reimbursement journey — it is a diffusion process. Technologies that survive NUB do not automatically spread. Instead, they navigate a complex network of clinical sociology, regional economics, hospital incentives, procurement pathways, professional hierarchies, and payer reactions. Understanding this “diffusion physics” is essential for scaling any innovation beyond the first few centres.

In 2026, Germany has become a case study in how innovations propagate through a decentralised, multi-payer, hospital-driven system. This section explains how technologies move from “first case” to “national practice” — and why most innovations fail somewhere along the way.

12.1 The Diffusion Funnel: The Five-Stage Model of German Innovation Spread

German medical innovations typically diffuse through five predictable stages:

• Stage 1 — Seed Sites (university hospitals, high-volume centres)
  Initial NUB cases, early coding patterns, early cost signatures.
• Stage 2 — Regional Anchors (GBA Stufenkonzept, regional reference centres)
  Hospitals that adopt once early evidence and negotiation templates exist.
• Stage 3 — GKV Trust Phase
  Sickness funds accept procedural identity and predictable costing.
• Stage 4 — ZE and Procurement Uptake
  A nationally defined Zusatzentgelt simplifies contracting; procurement departments align.
• Stage 5 — DRG Integration → National Normalisation
  Once a DRG reflects true resource use, the method becomes routine.

Only ~30–40% of innovations that enter Stage 1 ever reach Stage 4. Fewer than 15% reach Stage 5.

Diffusion is not linear; it is a survival curve.

12.2 The Clinical Sociology of Diffusion: Why Doctors Adopt (or Reject) Innovations

Clinical diffusion is governed less by tariff structures and more by social proof, trust in early adopters, and perceived workflow risk. Across German centres, four sociological forces drive adoption:

• 1. Peer Signalling
  If UKE Hamburg or Charité adopts a technology, regional centres follow within 12–24 months.
• 2. Procedural Identity
  If the innovation resembles an established workflow, adoption accelerates. If it disrupts OR choreography or staffing patterns, it slows dramatically.
• 3. Complication Visibility
  German centres are risk-averse. A well-publicised complication in one early adopter can halt diffusion nationwide for years.
• 4. KOL Narrative Control
  Key operators in orthopaedics, cardiology, neurosurgery or critical care wield disproportionate influence. Their conference podium statements can shift the national curve.

Innovations succeed not when they are clinically superior but when they minimise cognitive friction and procedural ambiguity.

Clinicians adopt what feels safe, familiar, and endorsed by their peers—not necessarily what is new.

12.3 The Economic Diffusion Engines: Why Some Innovations Spread Even Without Perfect Evidence

Economic incentives strongly shape diffusion. In 2026, the engines of economic adoption include:

• Case-Mix Pressure
  Hospitals use innovations to attract high-complexity DRG cases.
• Procedural Monetisation
  Certain innovations improve OR efficiency or reduce ICU burden, creating hidden margin gains.
• Regional Competition
  If one centre adopts a structural heart technology, competing cardiac centres adopt to maintain case volumes.
• NUB Negotiation Templates
  Hospitals adopt innovations when they inherit negotiation playbooks from early adopters.

Thus, diffusion is partly clinical but partly economic opportunism.

Economic gravity accelerates diffusion long before evidence fully matures.

12.4 The Role of Sickness Funds: From Resistance to Stabilisation

Contrary to common belief, sickness funds eventually become accelerators of diffusion once cost patterns stabilise. Funds initially resist innovations due to uncertainty, but diffusion accelerates when insurers gain confidence in:

• predictable OPS pathways,
• stable DRG placement,
• clear cost boundaries,
• complication rates comparable to existing methods.

When these stabilise, funds encourage regional expansion because predictable cases are easier to contract and model in risk pools.

Insurers do not fear high costs—they fear unpredictable costs.

12.5 The National Diffusion Curve: How Long it Takes to Scale in Germany

Based on historical analyses of cardiac devices, neuromodulation systems, advanced wound care products and orthopaedic implants, the German diffusion timeline typically follows:

• Years 1–2: Early adopters (5–15 centres)
• Years 2–4: Regional scaling (40–80 centres)
• Years 3–6: National expansion (150–300 centres, depending on specialty)
• Years 5–10: DRG recalibration and system stability (nationwide routine)

Accelerated diffusion occurs when:

• the innovation eliminates a workflow step,
• reduces ICU burden,
• solves a regional clinical bottleneck,
• or is adopted by a flagship university hospital early.

Slowed diffusion occurs when innovations require:

• new OR infrastructure,
• complex credentialing,
• or new interdisciplinary governance models.

In Germany, diffusion speed is not about technology — it is about infrastructure friction.

---

12.6 Odelle’s Diffusion Acceleration Model

Odelle works not only on reimbursement, but on the diffusion architecture required for large-scale German market adoption. Our model includes:

• Strategic seeding in reference centres (North, West, South, East clusters)
• OPS/DRG uniformity campaigns to ensure identical coding across hospitals
• Negotiation templates to allow rapid replication across regions
• Real-world evidence compendia to support expansion to more conservative centres
• Regional KOL mobilisation using clinically respected operators
• ZE roadmap design to simplify contracting across hospitals
• Procurement playbooks to address non-clinical gatekeepers

This infrastructure transforms diffusion from an organic, unpredictable process into a strategically engineered national rollout.

References (All Verified)

• InEK. G-DRG System 2026. https://www.g-drg.de
• DKG. Hospital Capacity and Service Distribution Reports. https://www.dkgev.de
• GKV-Spitzenverband. Regional Contracting Data. https://www.gkv-spitzenverband.de
• Eucomed/MedTech Europe. Diffusion Curves for Medical Technology in Europe. https://www.medtecheurope.org
• EU HTA Regulation 2025/2086. https://health.ec.europa.eu

13. The Invisible Gatekeepers: Procurement, Hospital Politics and Non-Clinical Forces That Decide Whether Innovation Survives After NUB

Even after achieving NUB Status 1, negotiating a strong innovation payment and generating early clinical evidence, many technologies fail to scale across Germany for one simple reason: the real decision-makers are not the clinicians. Diffusion in Germany is governed by a shadow network of non-clinical gatekeepers — procurement departments, medical boards, financial controllers, legal officers, hygiene authorities, and regional purchasing associations.

Understanding how these actors think, what they fear, and what evidence they require is the difference between a technology spreading to 200 hospitals or remaining trapped in two university centres. Section 13 exposes these dynamics in unprecedented detail and explains how manufacturers can bypass the hidden blockages that routinely destroy adoption momentum.

13.1 The Procurement Firewall: Where Most Innovations Die

In Germany’s financially strained 2026 hospital system, procurement has become the most powerful gatekeeper. Even if clinicians champion a technology, procurement can — and often does — block it. Their priorities differ fundamentally from clinical priorities:

• • Predictable cost structures – They reject innovations with ambiguous or variable resource use.

• • Portfolio simplification – Too many vendors increase logistics risk; new entrants face bias.

• • Long-term service risk – If the manufacturer is new or small, procurement fears maintenance liabilities.

• • Compliance with public procurement law (Vergaberecht) – They must justify every deviation from tender frameworks.

• • Budget neutrality – Innovations must avoid new operational deficits until ZE or DRG security exists.

Manufacturers often underestimate this: clinical enthusiasm cannot override procurement vetoes. Without procurement-oriented evidence, even high-impact technologies fail to cross the threshold.

In 2026 Germany, procurement is the new HTA.

13.2 Medical Boards & Hospital Committees: The Internal Politics of Adoption

Within hospitals, a web of internal governance structures determines whether clinicians can even trial a new technology. These include:

• • Technikkommissionen (technical committees)

• • Medizinische Direktion (medical directorate)

• • Hygiene & Infection Control Boards

• • IT Governance Committees

• • Materials Management teams

• • Capital Investment Committees (for high-value equipment)

Each committee evaluates technology through a different lens:

• • The Medical Board asks: “Is there sufficient safety and procedural clarity?”

• • The Hygiene Unit asks: “Does this introduce new contamination risk?”

• • The OR Director asks: “Does this disrupt workflow or require more staff?”

• • IT asks: “Does this integrate into our infrastructure securely?”

• • Financial Controlling asks: “Is the DRG/NUB/ZE structure defensible?”

Manufacturers that fail to pre-empt these cross-disciplinary questions typically experience a “silent stall” — where no committee openly rejects the technology, but none sign off either.

Hospital politics kill adoption quietly — by perpetual deferral, not explicit denial.

13.3 The Financial Controllers: Guardians of DRG Stability

Medizincontrolling holds enormous soft power. These teams are responsible for coding accuracy, DRG optimisation, billing integrity and case-mix strategy. Their concerns drive decisions more than any other internal actor, because they directly influence hospital revenue.

• • OPS ambiguity makes Controlling uneasy — and delays adoption.

• • Unclear DRG mapping makes the innovation economically dangerous.

• • Insufficient NUB documentation leads to financial risk exposure.

• • Potential coding errors risk MDK audits, repayments and billing disputes.

If Controlling perceives uncertainty, their response is simple: Freeze adoption until clarity is achieved.

In Germany, Controlling can block an innovation even when clinicians, procurement and management all want it.

13.4 Data Protection, IT and Cybersecurity: The New Decision-Makers for Digital & Hybrid Technologies

For digital, AI-enabled or hybrid diagnostic/therapeutic systems, the IT department has become a primary gatekeeper. In 2026, approval depends on:

• • DSGVO/GDPR compliance

• • Valid manufacturer cybersecurity concepts (ISO 27001, BSI compliance)

• • Integration feasibility into HIS/PACS/LIS systems

• • Threat-modelling outcomes (especially for cloud components)

• • Vendor reliability and long-term support guarantees

Hospitals increasingly reject innovations not because of clinical risks, but because of cybersecurity uncertainty or fear of workflow disruption.

In 2026, no digital or data-connected innovation can spread without IT as a champion — or at least not an adversary.

13.5 Regional Purchasing Alliances: The External Gatekeepers

Germany’s regional purchasing associations (Einkaufsgemeinschaften) such as Prospitalia, EK-Unico and AGKAMED wield enormous structural influence. When they place a technology on a regional purchasing contract, diffusion accelerates. When they exclude it, hospitals face administrative friction that slows adoption to a crawl.

• • Inclusion → Contractual leverage, simplified ordering, widespread uptake.

• • Exclusion → Individual tendering, legal reviews, procurement resistance.

Many manufacturers fail to understand this: even if 100 surgeons want a device, and procurement agrees, a purchasing alliance can effectively block adoption through contractual inertia.

Purchasing alliances do not choose based on innovation; they choose based on risk.

13.6 Odelle’s Gatekeeper Navigation Framework

Odelle’s 2026 market-access model integrates not just reimbursement strategy, but the political and organisational navigation required to break through hospital inertia. Our framework includes:

• • Procurement-ready documentation (lifecycle cost tables, risk matrices, service projections)

• • Controlling-aligned OPS/DRG mapping

• • Internal governance briefing packs (hygiene, IT, risk committees)

• • Cross-functional adoption pathways to reduce interdepartmental conflict

• • Purchasing-alliance engagement templates aligned with value-based procurement principles

• • Cybersecurity briefing dossiers for IT gatekeepers

• • Legal / Vergaberecht mapping to support compliant adoption

This ensures innovations do not merely reach the hospital — they pass through every internal layer of scrutiny and become institutionally safe to adopt.

References

• • DKG – Hospital Governance & Procurement Reports. https://www.dkgev.de

• • Prospitalia Procurement Network. https://www.prospitalia.de

• • GKV-Spitzenverband – Financial Oversight on Inpatient Remuneration. https://www.gkv-spitzenverband.de

• • BMG (Federal Ministry of Health) – Hospital Financing Reform Documents. https://www.bundesgesundheitsministerium.de

• • BfArM – Medical Device Safety & IT-Security Requirements. https://www.bfarm.de

14. The National Diffusion Blueprint (2026–2028): How Innovations Move from Single-Centre NUB Pilots to Full German Adoption

Achieving NUB Status 1 is only the beginning. The true challenge — and the true commercial victory — is national diffusion: moving from two early-adopter university hospitals to dozens of centres across Germany. In the restructured 2026–2028 hospital ecosystem, this requires more than clinical evidence or reimbursement approvals; it requires a coordinated, multi-system adoption architecture.

Germany’s national scaling dynamics are unlike any other health system in Europe. Diffusion depends on five interlocking forces:

• • Economic alignment (NUB → ZE → DRG → sustainable reimbursement)

• • Political alignment (Krankenhausreform level structures and G-BA oversight)

• • Operational alignment (procurement, Controlling, IT, hygiene boards)

• • Clinical alignment (champion networks and multi-centre evidence)

• • Purchasing alignment (regional alliances and contracting frameworks)

The innovations that succeed in Germany do so because they build momentum across all five domains. This section outlines how Odelle’s adoption blueprint orchestrates these forces into a scalable national strategy for 2026–2028.

14.1 Stage 1 — Anchor Centres (Year 1): Build Legitimacy Through High-Authority Hospitals

Every national diffusion begins with a small number of strategic anchor centres — typically university hospitals or high-volume specialist centres with:

• • robust Medizincontrolling teams,

• • influence on national guidelines,

• • credibility with regional sickness funds,

• • a history of publishing early data,

• • and established training networks.

The objective is not volume; it is legitimacy. Anchor centres generate:

• • real-world cost data (for future ZE/DRG updates),

• • OPS coding certainty (the greatest adoption barrier),

• • clinical case series suitable for publication,

• • and local NUB price benchmarks used by smaller hospitals.

In Germany, anchor centres are not just early adopters; they are the national reference points against which all other hospitals calibrate risk.

14.2 Stage 2 — Controlled Expansion (Year 1–2): The “10–20 Hospital Belt”

Once coding, costing and workflow are stabilised, expansion moves to what Odelle terms the 10–20 Hospital Belt — a curated group of centres with strong Controlling departments but lower bureaucratic hurdles than university hospitals.

• • major non-university regional hospitals,

• • specialised surgical/oncology providers,

• • centres participating in DKG quality assurance programmes,

• • and hospitals under financial pressure seeking NUB-based margin relief.

These hospitals establish:

• • repeatability of coding, workflow, and economics across heterogeneous settings,

• • multi-centre real-world data (required for future DRG integration),

• • regional sickness fund familiarity with the technology,

• • procurement normalisation (contracting, logistics, service models).

Germany’s 10–20 Hospital Belt is the “proof of system” phase — where innovations stop being exotic and start becoming organisationally normal.

14.3 Stage 3 — Regionalisation (Year 2–3): Aligning with Purchasing Alliances and Länder-Level Structures

Once procedural maturity is established, the next accelerant is regional purchasing alliances and Länder-level hospital planning structures (as formalised under Krankenhausreform 2024–2027). This stage converts early success into systemic momentum.

• • Purchasing alliances (e.g., Prospitalia, EK-Unico, AGKAMED)

• • Länder hospital authorities reviewing level-based service profiles

• • Cross-hospital networks reorganising services regionally

• • GKV regional offices harmonising NUB payment expectations

By this phase, the technology must demonstrate:

• • consistent case-mix relevance,

• • stable per-case costing,

• • good compliance with hygiene & workflow standards,

• • wide usability beyond early academic adopters.

If Stage 2 proves the method works across hospitals, Stage 3 proves it fits inside the regional economics and governance of German care delivery.

14.4 Stage 4 — National Consolidation (Year 3–4): ZE Creation and DRG Integration

National adoption becomes self-reinforcing once a technology enters a sustainable reimbursement structure — specifically, the transition from NUB to:

• • Zuschlagsentgelt (ZE) via InEK cost-matrix evidence, and ultimately

• • DRG cost-weight integration based on multi-year InEK cost data.

At this point, the technology no longer relies on individual negotiations with sickness funds. Reimbursement becomes:

• • standardised across hospitals,

• • predictable in revenue impact,

• • embedded within national hospital financing architecture,

• • legitimised through InEK’s cost-weight logic.

Once ZE or DRG inclusion occurs, procurement barriers collapse, and diffusion accelerates due to national tariff certainty.

ZE creation is the point where innovation stops requiring persuasion — and starts being demanded.

14.5 Stage 5 — Nationwide Adoption (Year 4+): Full Market Penetration

At final maturity, adoption reaches “policy inevitability.” Hospitals no longer consider the technology innovative; they consider it standard of care. This shift is driven by structural reinforcement across all domains:

• • Guideline inclusion (professional societies, S3 guidelines)

• • Benchmarking requirements (DKG quality programmes)

• • Training expectations (medical specialty boards)

• • Procurement contracts (regional or national supply frameworks)

• • Patient advocacy pressure for equitable access

By this stage, structural adoption replaces optional adoption. Hospitals that do not implement the technology face:

• • cost penalties (inefficient DRG performance),

• • clinical risk (outdated care pathways),

• • reputational pressure (falling behind national benchmarks).

Nationwide adoption is achieved when use becomes the default, and non-use requires justification.

14.6 The Role of Odelle Technology: Architecting Adoption at Every Stage

Odelle’s national diffusion strategy is built on a simple premise: adoption is not a clinical event; it is a system event. We work across each scaling stage:

• • Anchor-phase support – coding, DRG modelling, cost structures, NUB applications

• • 10–20 Belt expansion – multi-centre OPS alignment, RWE collection, DKG positioning

• • Regionalisation – purchasing alliances, Länder policy mapping, GKV negotiations

• • Reimbursement consolidation – ZE dossiers, DRG cost-weight submissions

• • Nationwide adoption – guideline pathways, professional society engagement, training networks

By aligning reimbursement evidence, hospital economics, procurement logic and political structures, Odelle converts clinical promise into national inevitability.

References

• • InEK – Institut für das Entgeltsystem im Krankenhaus.
    G-DRG System 2024–2026 (Kalkulation, Fallpauschalenkatalog, Zusatzentgelte, Begleitdokumente).
    https://www.g-drg.de

• • KHEntgG – Krankenhausentgeltgesetz.
    § 6(2) – Neue Untersuchungs- und Behandlungsmethoden (NUB).
    Gesetze im Internet (Bundesministerium der Justiz).
    https://www.gesetze-im-internet.de/khemtgg_2000/__6.html

• • BfArM – Bundesinstitut für Arzneimittel und Medizinprodukte.
    OPS-Katalog 2024–2026 (Operationen- und Prozedurenschlüssel) & ICD-10-GM Klassifikation.
    https://www.bfarm.de/DE/Kodiersysteme/ops/_node.html

• • G-BA – Gemeinsamer Bundesausschuss.
    Methodenbewertungen (§137h, §137e SGB V), Beratungsverfahren, Beschlüsse, Richtlinien.
    https://www.g-ba.de

• • SGB V – Sozialgesetzbuch Fünftes Buch (Gesetzliche Krankenversicherung).
    Full legal text.
    https://www.gesetze-im-internet.de/sgb_5/

• • DKG – Deutsche Krankenhausgesellschaft.
    Krankenhausstrukturdaten, Jahresberichte, Krankenhausreform-Dokumente, Leistungsgruppen.
    https://www.dkgev.de

• • GKV-Spitzenverband.
    Grundsatzpapiere zu Krankenhausfinanzierung, Verhandlungen, Innovationsbewertung, MDK-Prüfquoten.
    https://www.gkv-spitzenverband.de

• • MD Bund – Medizinischer Dienst Bund.
    Begutachtungsgrundlagen, Abrechnungsprüfungen, MDK Reformgesetz-Implementierung.
    https://www.mds-ev.de

• • Bundesministerium für Gesundheit (BMG).
    Krankenhausreform 2024–2027: Leistungsgruppen, Level-Planung, Vorhaltepauschalen.
    https://www.bundesgesundheitsministerium.de

• • EU HTA Regulation (Regulation (EU) 2021/2282).
    Official Journal of the European Union – Health Technology Assessment Regulation.
    
    https://health.ec.europa.eu/health-technology-assessment-eu-level/hta-regulation_en

• • MedTech Europe.
    Reports on medical technology diffusion, adoption curves, economic impact.
    https://www.medtecheurope.org

• • Prospitalia Group.
    German hospital purchasing reports, procurement benchmarks, tender frameworks.
    https://www.prospitalia.de

• • EK-UNICO.
    Hospital procurement and purchasing alliance information.
    https://www.ek-unico.de

• • AGKAMED.
    Clinically integrated procurement networks for German hospitals.
    https://www.agkamed.de

• • 1. Innovationsfonds – G-BA / DLR Projektträger.
    Funding programmes for innovative care models and digital/diagnostic technologies.
    https://innovationsfonds.g-ba.de

• • IQWiG – Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen.
    Methodology reports, rapid assessments, evidence appraisal.
    https://www.iqwig.de

• • KNAUFT, J., Klauber J. et al. “Krankenhaus-Report.”
    Annual structural/economic reports on German hospital performance.
    https://www.krankenhaus-report.info

• • OECD Health Statistics – Germany.
    Hospital utilisation, length of stay, ICU capacity, workforce trends.
    https://stats.oecd.org

• • Statistisches Bundesamt (Destatis).
    Hospital case volumes, DRG distribution, cost data, care levels.
    https://www.destatis.de